CEACAM5 and neoplasm: The CD3 monovalent BsAb variant, which does not carry the CEACAM5-binding arm, did not induce relevant killing of the tested tumor cells (killing < 4%, eightfold less compared to NILK-2301, LS-174T), confirming that NILK-2301-mediated killing is CEACAM5-dependent.